Another CRISPR Biotech Goes Public

CRISPR Therapeutics, the company started by a pioneer of the gene editing technology, plans to raise $90 million from an initial public offering.

Written byBob Grant

| 1 min read

Listen with Speechify

0:00

1:00

CRISPR Therapeutics floats a $90 million IPO. WIKIMEDIA, ERNESTO DEL ADUILA III, NHGRIBiotech investors will soon have one more CRISPR/Cas9-based company to back, after CRISPR Therapeutics filed for an initial public offering (IPO) on Friday (September 9). The firm, which was cofounded by CRISPR/Cas9 pioneer Emanuelle Charpentier as Inception Genomics in 2013, is looking to raise $90 million from the IPO and will join the ranks of Intellia Therapeutics and Editas Medicine, which both went public earlier this year. Like the other publicly traded, gene-editing companies, CRISPR Therapeutics will sell its shares on the Nasdaq exchange.

According to the IPO registration document that CRISPR Therapeutics filed with the US Securities and Exchange Commission, the firm brokered a pretty sweet deal before the IPO even gets underway. Bayer—the company that CRISPR Therapeutics has been collaborating with on Casebia, a joint effort to develop gene therapies—has agreed to kick in $35 million in a separate deal at the IPO price.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Join for free today

Already a member? Login Here

Meet the Author

Bob Grant
From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.
View Full Profile